Phathom Pharma Upgraded by Barclays to Overweight $18 Target
Barclays lifts Phathom Pharmaceuticals to Overweight with an $18 target, citing a stronger 2026 revenue trajectory an...
This guide compares the cost profiles of Index Fund and Target Date Retirement funds, highlighting where charges differ and how to choose cost-efficient options.
28,430 articlesBarclays lifts Phathom Pharmaceuticals to Overweight with an $18 target, citing a stronger 2026 revenue trajectory an...
Biotech stocks often ride a volatile wave of news, milestones, and insider moves. In the last year, one biotechnology...
The Fed left its policy rate unchanged, but a veteran observer says the odds of a hike this year remain intact as War...
The AI hype loop is loud, but investors want results. This piece breaks down what mark zuckerberg admitted agents cou...
Steve Case frames AI as a major growth engine with job-market risks. The Silicon Valley-to-Main Street debate acceler...
Palantir Technologies stock popped on a rally driven by legal news and AI momentum. This guide explains what happened...
Analysts tout gains for an overlooked tech name, but the upside may be clouded by rising costs, competition, and macr...
As August approaches, a key SpaceX catalyst coming could shift the balance for investors. This guide breaks down what...
When Ringo Starr performed in San Diego, the night wasn’t just about nostalgia. The All Starr Band’s rotating lineup ...
Rocket Lab’s stock faced a sharp pullback before rebounding in March. This article breaks down what caused the drop, ...
Two well-positioned tech companies could be the catalysts for a multi-year fortune-building journey. This guide break...
Mining stocks are delivering outsized gains in a fresh gold rally, outpacing bullion as risk assets rebound and infla...